Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice
about
Animal and in silico models for the study of sarcomeric cardiomyopathiesTargets for therapy in sarcomeric cardiomyopathiesAAV9-mediated gene transfer of desmin ameliorates cardiomyopathy in desmin-deficient mice.The embryological basis of subclinical hypertrophic cardiomyopathyResearch priorities in sarcomeric cardiomyopathiesTargeting the sarcomere to correct muscle functionCorrection of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy.Epigallocatechin-3-Gallate Accelerates Relaxation and Ca2+ Transient Decay and Desensitizes Myofilaments in Healthy and Mybpc3-Targeted Knock-in Cardiomyopathic Mice.Approaching the facts between genetic mutation and clinical practice of hypertrophic cardiomyopathy: A case report with RAF1 770C>T mutant.Cardiac myosin binding protein C regulates postnatal myocyte cytokinesis.Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-CAlterations in sarcomere function modify the hyperplastic to hypertrophic transition phase of mammalian cardiomyocyte development.The genetic landscape of cardiomyopathy and its role in heart failure.I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model.Preventing pediatric cardiomyopathy: a 2015 outlook.Precision medicine approach to genetic cardiomyopathy.Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity.The Role of Cardiac Myosin Binding Protein C3 in Hypertrophic Cardiomyopathy-Progress and Novel Therapeutic Opportunities.Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes.Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model.Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies.Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.Activation of Autophagy Ameliorates Cardiomyopathy in Mybpc3-Targeted Knockin Mice.Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy.Precision medicine for cardiovascular disease : Learning lessons from cardiomyopathies.S100A4 as a Target of the E3-Ligase Asb2β and Its Effect on Engineered Heart Tissue
P2860
Q26865437-604E215F-8835-419D-8CF2-91B21967E1E8Q27027023-4DEFD96C-D2AE-4A86-81DC-437538EE9D73Q27323272-3B5DC2A1-43BC-44B2-8E17-EF3ACFC272D9Q27342687-A39B3FC4-44F9-4031-A714-D07D74A4AFB4Q27694507-0BB473F7-1E5E-4D3B-ACD7-9EEFA5A4620CQ28260629-897B02C8-0BE5-49D7-B857-DDCE1DB93398Q30411331-5271CFAB-CA44-4178-A4C2-6A8F78AA2DFBQ30830714-44377C01-42E0-4A14-9517-FC1ED7F8D893Q33595276-35DB00E7-50F6-4B15-BC81-5D4DF3FD6BCFQ35895661-9C590E67-ABFD-4EC9-9CD1-BF1B75BFA901Q36341946-3EF94BFB-3CE7-4C4E-9F22-A3A4D2889A67Q37646848-92A39725-8F5E-4275-BE2B-CB56227FA7A8Q38343935-BD22E556-A5E0-4A86-BBBC-3BB030DD7F5FQ38635697-104AF7E3-342D-431C-A51A-1844E6360DC3Q38662111-E2EFE7BD-EE21-4A52-BB40-B2E9E4EE7789Q38666336-561E6C30-4481-4025-83C7-3C215A008132Q38684383-57946CBB-A579-4143-95C8-F6A7624DF4E6Q38978665-7BAC8986-B744-4D6C-8C7F-F3A1E234CAC5Q40156224-FE475A3A-4193-46B9-A0DD-F3115BC2A80DQ41203153-7D83C53F-A318-47A2-93B2-5380E024EE1AQ41664792-AC127081-1D3C-4FF4-A045-FBE4F8695B01Q41700317-5A3E5CBF-FD10-4087-8D57-DA660AF30166Q42504304-6961C1B7-51A1-464E-B7F3-0701DECA1B5AQ42515078-E588F507-2E36-410D-9B0B-BD9C9E622B25Q47665566-E635FCAC-A64B-42BB-8DBC-184DF4242014Q48747768-CE85A591-A3A8-4D7C-B297-2A8AE87D40F9Q50424267-E577B1C0-FE16-468B-8259-18A4A2F38817Q57072975-C412340B-E3BA-4C66-A9ED-DE3418595ABE
P2860
Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mybpc3 gene therapy for neonat ...... erm disease prevention in mice
@ast
Mybpc3 gene therapy for neonat ...... erm disease prevention in mice
@en
Mybpc3 gene therapy for neonat ...... erm disease prevention in mice
@nl
type
label
Mybpc3 gene therapy for neonat ...... erm disease prevention in mice
@ast
Mybpc3 gene therapy for neonat ...... erm disease prevention in mice
@en
Mybpc3 gene therapy for neonat ...... erm disease prevention in mice
@nl
prefLabel
Mybpc3 gene therapy for neonat ...... erm disease prevention in mice
@ast
Mybpc3 gene therapy for neonat ...... erm disease prevention in mice
@en
Mybpc3 gene therapy for neonat ...... erm disease prevention in mice
@nl
P2093
P2860
P50
P3181
P356
P1476
Mybpc3 gene therapy for neonat ...... erm disease prevention in mice
@en
P2093
Alexander Dutsch
Andrea Stoehr
Doreen Stimpel
Florian Weinberger
Hugo A Katus
Julia Mourot-Filiatre
Oliver J Müller
Paul J M Wijnker
Thomas Eschenhagen
Thomas Voit
P2860
P2888
P3181
P356
10.1038/NCOMMS6515
P407
P577
2014-12-02T00:00:00Z
P5875
P6179
1016814386